In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...

Cornerstone Robotics Ltd. raised more than $70 million in a series C round to expand its international footprint and ...

As 2025 makes its debut, one of the topics gaining momentum in health care is the diagnosis and potential treatment of neurodegenerative diseases, a scourge that threatens to overwhelm society and ...

Day two of the J.P Morgan Healthcare Conference rolled on with positive data from Sling Therapeutics Inc. that is leading the company to a phase III study in treating thyroid eye disease. The ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Intra-Cellular recently guided to at least $5 billion in peak Caplyta sales. Intra-Cellular’s stock was trading at $127.48, up $32.61, or 34%. J&J’s stock (NYSE:JNJ) was selling for $143.39, up $1.34.

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...

In the first patenting to emerge from Carlsbad, Calif.-based Biologic Input Output Systems Inc., its chief development ...

Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA ...

Quanterix Corp. plans to merge with Akoya Biosciences Inc., in an all-stock transaction that both companies hope will bolster ...

Researchers from Boehringer Ingelheim Pharma GmbH & Co KG have published preclinical data for their novel pan-KRAS inhibitors ...